By Jake King
Shares of Chelsea Therapeutics (NASDAQ:CHTP) opened sharply higher on news Wednesday that FDA has provided the company with a new pathway for approval of Northera. Northera is the company's primary value driver and a treatment for hypotension (low blood pressure associated with dizziness & fainting) in patients with Parkinson's Disease and other neurodegenerative conditions. Results of the latest Phase III trial (the '306b trial) reported in early December were positive, but previously, the FDA gave guidance that results of this trial as well as several other Phase III trials ('301, '302, and '306a) would not be enough to obtain approval, despite a positive recommendation by an FDA Panel last February. We speculated when the 306b data were released in December that the FDA could take another look at the evidence behind Northera and reconsider their requirements for approval.
Based on the company's announcement today, that is exactly what happened, which makes sense given that Northera addresses an unmet medical need and has demonstrated a benefit to patients. In the company's press release Wednesday, FDA comments on the 306b trial results were encouraging. In a meeting between the agency and Chelsea, the FDA stated, "data strongly demonstrating a short-term clinical benefit (e.g., improvement in symptoms or ability to function) of Northera (droxidopa) in patients with NOH would be adequate for approval, with a possible requirement to verify durable clinical benefit post-approval." The key change here is that FDA has now indicated that a short-term benefit could be used for approval and that long-term "durable" effects would be used as supportive efficacy data, and could be tested for following approval.
Given that CHTP has already demonstrated short-term benefits with Northera in several Phase III trials, specifically with regard to dizziness (Item #1 on the OHQ scale), the company plans to re-assemble its new drug application (NDA) for Northera and submit it in 2Q 2013. The company stated that it will file its updated application as a Class II NDA re-submission, which starts a 6-month review clock with potential approval by year-end. Conservatively assuming that Northera could generate at least $50M in annual sales, a typical 4x multiple on peak sales could value CHTP at $200M, double the current value of the company.
Importantly, the company still has over $28M in cash, enough to get to FDA approval and beyond. Despite the sharp run-up on Wednesday's news, we believe upside in CHTP is still significant, particularly, if the drug can be developed in other indications and achieve sales north of $50M annually. At ~$1.50 per share, and with new guidance from the FDA that currently-generated Phase III data could be enough for approval, we believe CHTP is a good bet.
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article.
Additional disclosure: PropThink is a team of editors, analysts, and writers. This article was written by Jake King. We did not receive compensation for this article, and we have no business relationship with any company whose stock is mentioned in this article. Use of PropThink’s research is at your own risk. You should do your own research and due diligence before making any investment decision with respect to securities covered herein.You should assume that as of the publication date of any report or letter, PropThink, LLC and persons or entities with whom it has relation ships (collectively referred to as "PropThink") has a position in all stocks (and/or options of the stock) covered herein that is consistent with the position set forth in our research report. Following publication of any report or letter, PropThink intends to continue transacting in the securities covered herein, and we may be long, short, or neutral at any time hereafter regardless of our initial recommendation. To the best of our knowledge and belief, all information contained herein is accurate and reliable, and has been obtained from public sources we believe to be accurate and reliable, and not from company insiders or persons who have a relationship with company insiders. Our full disclaimer is available at www.propthink.com/disclaimer.